Market Overview:
The global prefilled syringes market size reached US$ 7.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 11.8 Billion by 2028, exhibiting a growth rate (CAGR) of 8.8% during 2023-2028.
A prefilled syringe is a single-dose packet of injectable vaccines that is disposable in nature. The usage of prefilled syringes significantly lowers the chances of drug contamination as it avoids the potential admixture-related contamination risks when syringes are inserted into a drug vial to draw out a dose. Combining this with a pre-sterilized syringe further increases safety, enables the easy and quick delivery of drugs in the case of emergencies, and eliminates the additional on-site vial cleaning and de-pyrogenation processes. Consequently, they are a preferred option to administer the drugs via the parenteral route for delivering a wide range of injectables, such as biosimilar and biologics.
Prefilled Syringes Market Trends:
The global market is primarily driven by the increasing incidences of chronic diseases, including diabetes and autoimmune diseases. This is further supported by the growing demand for treating chronic medical conditions using biological drugs in pre-fillable syringes. In addition to this, the widespread adoption of the prefilled syringe products by healthcare professionals and the escalating number of new product launches by key players are also fostering the market. Moreover, with significant technological advancements, the implementations of self-injecting parenteral devices are also increasing, which, in turn, is contributing to the market growth. The market is also driven by the rising geriatric population on the global level and growing investments in improving the overall healthcare infrastructure. Other factors, such as supportive government regulations regarding needlestick legislation, the rising consciousness regarding the advantages of prefilled syringes, the widespread preference for home-based healthcare, and the increasing popularity of biologics and biosimilars across the pharmaceutical settings, are further creating lucrative growth opportunities in the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global prefilled syringes market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on design, material, closing system, application and end user.
Breakup by Design:
- Single-chamber Prefilled Syringes
- Dual-chamber Prefilled Syringes
- Customized Prefilled Syringes
Breakup by Material:
- Glass Prefilled Syringes
- Plastic Prefilled Syringes
Breakup by Closing System:
- Staked Needle System
- Luer Cone System
- Luer Lock Form System
Breakup by Application:
- Diabetes
- Anaphylaxis
- Rheumatoid Arthritis
- Oncology
- Others
Breakup by End User:
Breakup by Region:
- North America
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, B. Braun Melsungen AG, Baxter International Inc., Bayer AG, Becton Dickinson and Company, Cardinal Health Inc., Catalent Inc., Fresenius SE & Co. KGaA, Gerresheimer AG, Nipro Corporation, Schott AG, Terumo Corporation and West Pharmaceutical Services Inc.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2022 |
Historical Period |
2017-2022 |
Forecast Period |
2023-2028 |
Units |
US$ Billion |
Segment Coverage |
Design, Material, Closing System, Application, End User, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
Abbott Laboratories, B. Braun Melsungen AG, Baxter International Inc., Bayer AG, Becton Dickinson and Company, Cardinal Health Inc., Catalent Inc., Fresenius SE & Co. KGaA, Gerresheimer AG, Nipro Corporation, Schott AG, Terumo Corporation and West Pharmaceutical Services Inc. |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |